Diffusion MRI Analysis for Axonal Loss and Myelin Degradation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current noninvasive methods, such as MRI, struggle to differentiate between axonal loss and myelin degradation in neurodegenerative diseases, as these subtle microstructural changes are below the nominal spatial resolution of MRI scanners, making it difficult to quantify the degree of these pathological processes effectively.
Innovation Solution
The development of systems, methods, and computer-accessible mediums that use diffusion measurements and Monte Carlo simulations to determine axonal loss and myelin degradation by analyzing tortuosity and axonal water fraction, employing models based on axonal geometry and applying contour grids and analytical relations to differentiate between the two processes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If MRI is used to probe soft tissues, then noninvasive measurement is achieved, but measurement precision deteriorates because subtle microstructural changes are below the nominal spatial resolution of MRI scanners
Solution Approach 1:
The patent changes the measurement parameters from standard MRI to diffusion-weighted MRI with non-Gaussian diffusion metrics. By measuring tortuosity and axonal water fraction through diffusion properties rather than spatial resolution, the system can detect microstructural changes at the micrometer scale without requiring higher spatial resolution imaging.
2Device complexity
If standard MRI spatial resolution is used, then device complexity is kept simple, but measurement precision deteriorates because it cannot resolve micrometer-scale changes in axonal loss and myelin degradation
Solution Approach 1:
The patent replaces the mechanical/spatial resolution approach of MRI with a diffusion-based measurement approach. Instead of relying on the physical resolution limits of the MRI scanner, the system uses diffusion-weighted measurements and Monte Carlo simulations to infer micrometer-scale structural changes from macroscopic diffusion properties, substituting direct spatial imaging with indirect diffusion-based probing.
3Measurement precision
If diffusion measurements and Monte Carlo simulations are used, then measurement precision improves for detecting axonal loss and myelin degradation, but device complexity increases due to the need for non-Gaussian diffusion-weighted MRI and analytical modeling
Solution Approach 1:
The patent performs preliminary Monte Carlo simulations to establish the relationship between diffusion properties and microstructural parameters before actual measurement. By pre-calculating the expected diffusion behavior for various axonal loss and myelin degradation scenarios, the system creates lookup tables or analytical models that can be directly applied to patient data, avoiding the need for complex real-time simulations during clinical measurement.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables the accurate differentiation and quantification of axonal loss and myelin degradation, providing valuable clinical insights for diagnosing and assessing treatment efficacy in neurodegenerative and myelin-related disorders, using non-Gaussian diffusion-weighted MRI and diffusion kurtosis metrics.
Implementation Method 1
receiving a first input variable based on a measure of diffusion of an axonal space or structure
Data Source
AI summary
Method, system and computer-accessible medium for determining at least one of axonal loss or myelin degradation can be provided. For example, it is possible to receive data based on at least one of a measure of diffusion of an axonal structure or a measure of a density of axons, and determine axonal loss and/or myelin degradation based on the data. The determination can be based on axonal geometry of at least one parallel tube.